Sugi Predict

Sugi Predict / Compounds / SCHEMBL3347086

SCHEMBL3347086

SCHEMBL3347086

COc1ccc(C(=O)c2ccccn2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.68
▸ NPC1 O15118 5/20 0.68
▸ PKM P14618 3/20 0.68
▸ SMN1; SMN2 Q16637 3/20 0.68
▸ CDK5 Q00535 2/20 0.68
▸ PAX8 Q06710 2/20 0.68
▸ CDK5R1 Q15078 2/20 0.68
▸ HPGD P15428 1/20 0.68
▸ KMT2A Q03164 6/20 0.66
▸ MAPT P10636 6/20 0.63
▸ KDM4E B2RXH2 4/20 0.58
▸ MEN1 O00255 4/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ SCD O00767 1/20 0.58
▸ LMNA P02545 2/20 0.58
▸ HTT P42858 2/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ F2 P00734 1/20 0.57
▸ POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28337456 0.85 KDM4E (0.69) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL11816880 0.85 RAB9A (0.67) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL20412776 0.84 RAB9A (0.54) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL13600088 0.83 MAPT (0.70) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL11609875 0.83 KMT2A (0.71) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL7547074 0.83 RAB9A (0.64) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL15988688 0.81 RAB9A (0.62) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL3870748 0.81 RAB9A (0.61) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL743166 0.81 KMT2A (0.72) RAB9ANPC1PKMSMN1; SMN2CDK5
SCHEMBL29485021 0.81 KMT2A (0.72) RAB9ANPC1PKMSMN1; SMN2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233799-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2021-05-19 — — EP disclosed
US-10752588-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-08-25 — — US disclosed
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-11-14 — — US disclosed
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-01-24 — — US disclosed
US-9908877-B2 Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-03-06 — — US disclosed
EP-3233799-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 — — EP disclosed
US-20160264571-A1 IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-09-15 — — US disclosed
WO-2016100823-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 — — WO disclosed
US-9371448-B2 Imidazo[1,5-a]pyridinium ion fluorophores, and methods of making and using the same INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-06-21 — — US disclosed
US-20140248646-A1 IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2014-09-04 — — US disclosed
US-8637500-B2 Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2014-01-28 — — US disclosed
US-8637500-B2 Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2014-01-28 — — US disclosed
US-8637500-B2 Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2014-01-28 — — US disclosed
EP-2376455-B1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC (US) 2012-11-14 — — EP disclosed
EP-2376455-B1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC (US) 2012-11-14 — — EP disclosed
WO-2010077992-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-07-08 — — WO disclosed
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-24 — — US disclosed
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-24 — — US disclosed
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-24 — — US disclosed
US-3985887-A BRONCHODILATORS SMITHKLINE CORPORATION (US) 1976-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264571-A1 IMIDAZO[1,5-a]PYRIDINIUM ION FLUOROPHORES, AND METHODS OF MAKING AND USING THE SAME H1-5, IK, H1-0 RAB9A 2384/4885NPC1 1974/4885PKM 1749/4885
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 RAB9A 906/4885NPC1 2458/4885PKM 3719/4885
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 RAB9A 906/4885NPC1 2458/4885PKM 3719/4885
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE4A, PDE7A, PDE4D RAB9A 452/4885NPC1 4493/4885PKM 2654/4885
US-10752588-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 RAB9A 906/4885NPC1 2458/4885PKM 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.